ReviewInternational journal of molecular sciences2012
Deciphering the molecular nature of ovarian cancer biomarker CA125.
Review in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A highly sensitive photoelectrochemical immunosensor for cancer antigen (CA 125) based on a nanoplatform of carbon dots and cadmium sulphide.RSC advances · 2025Article
- Inflammatory Indices vs. CA 125 for the Diagnosis of Early Ovarian Cancer: Evidence from a Multicenter Prospective Italian Cohort.Journal of personalized medicine · 2025Article
- Mapping the Binding Sites of CA125-Specific Antibodies on a Revised Molecular Model of MUC16.Cancers · 2025Article
- Differential diagnosis of benign and malignant vertebral compression fractures based on CT radiomics model.Frontiers in oncology · 2025Article
- Potential and application of abortive transcripts as a novel molecular marker of cancers.World journal of experimental medicine · 2024Review
- A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.Cancer research communications · 2024Article
- Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies.bioRxiv : the preprint server for biology · 2023Article
- Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies.Cancer biomarkers : section A of Disease markers · 2023Article
- Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers.Current oncology (Toronto, Ont.) · 2022Review
- Novel Optical Biosensor Based on a Nano-Gold Coated by Schiff Base Doped in Sol/Gel Matrix for Sensitive Screening of Oncomarker CA-125.ACS omega · 2021Article
- Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.PloS one · 2021Article
- High expression of ZNF93 promotes proliferation and migration of ovarian cancer cells and relates to poor prognosis.International journal of clinical and experimental pathology · 2020Article
- Biosensors Incorporating Bimetallic Nanoparticles.Nanomaterials (Basel, Switzerland) · 2015Review
- Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood.BBA clinical · 2014Article
- In 2014, can we do better than CA125 in the early detection of ovarian cancer?World journal of biological chemistry · 2014Review
- Diagnostic Difficulties in Woman with Crohn's Disease, Ascites, and Elevated Value of Serum CA125 Antigen.Case reports in medicine · 2014Article
- Exploring the glycosylation of serum CA125.International journal of molecular sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ovarian cancer biomarker CA125 has been extensively investigated over the last 30 years. The knowledge about the exact molecular nature of this protein, however, remains fragmented. This review provides an overview of the structural research regarding CA125, and presents an orthogonal verification method to confirm the identity of this molecule. The need for independent identification of CA125 is exemplified by several reports where mutually exclusive data concerning the existence of isoforms and the glycan moieties is presented. Mass spectrometry can overcome the pitfalls of a single detection/identification method such as antibody probing. Independent verification of CA125 identity in characterization studies will help establish a refined model of its molecular structure that will promote the development of new approaches for diagnosis, prognosis and therapy of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.